Otsuka Novel Products

Name

Otsuka Novel Products

Legal name

Otsuka Novel Products GmbH

Website

https://otsuka-onpg.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Otsuka Novel Products GmbH is a Munich-based pharmaceutical affiliate of Otsuka Pharmaceutical Co., Ltd. that develops and distributes Deltyba (delamanid) for treating multidrug-resistant tuberculosis in adults and children across European markets.

Ownership category

akta.pro rank

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription-only medicine Deltyba (delamanid) for treatment of multidrug-resistant tuberculosis. Sold to authorized healthcare professionals, institutions, and wholesalers with appropriate distribution licenses. Pricing in EUR, CPT place of consignee.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Otsuka Novel Products GmbH manufactures and distributes Deltyba (delamanid), a prescription-only medicine for the treatment of multidrug-resistant tuberculosis (MDR-TB). The product is offered as 50 mg film-coated tablets for adults and 25 mg dispersible tablets for paediatric patients, and is supplied exclusively to authorized wholesalers and healthcare institutions in European markets through tightly regulated channels compliant with the German Drug Act.

Product overview

Otsuka Novel Products GmbH operates as a pharmaceutical company focused on tuberculosis treatment and research. The core product portfolio centers on Deltyba® (delamanid), available in 50 mg film-coated tablets for adults and 25 mg dispersible tablets for children, both prescription medicines for multidrug-resistant TB (MDR-TB). The company also produces educational publications under the FighTBack brand that share patient stories and TB awareness content from around the world. The Global TB Programme encompasses four strategic pillars: Innovative R&D, Responsible Access to Medicines, Collaboration, and Curbing Drug Resistance.

Differentiator

Problem solved

Functional benefit

Brands

• Deltyba: Deltyba (delamanid) - a prescription medicine for the treatment of multidrug-resistant tuberculosis (MDR-TB). Available in 50mg film-coated tablets and 25mg dispersible tablets.

Products and services

• Deltyba 50 mg film-coated tablets Prescription medicine containing delamanid as the active substance, indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults. Distributed exclusively to authorized wholesalers and healthcare institutions across European markets including Austria, France, Germany, Italy, Spain, and others.
• Deltyba 25 mg dispersible tablets Paediatric formulation of delamanid for the treatment of MDR-TB in children, designed as a dispersible tablet for easier administration to address the significant gap in child-friendly tuberculosis treatments.

Quantifiable outcome

• 71% treatment success rate for MDR-TB patients enrolled on treatment
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• PAN-TB Collaboration (Project to Accelerate New Treatments for Tuberculosis)coreStrategic or Co-development PartnerA consortium of philanthropic, non-profit and private sector organisations who aim to develop treatment regimens for TB patients, no matter their drug resistance status. Otsuka is a member collaborating on paradigm-shifting technologies for TB treatment.
• UNITE4TB (Academia and Industry United Innovation and Treatment for Tuberculosis)coreStrategic or Co-development PartnerA global public-private consortium of academic institutions, pharmaceutical companies, and research organizations working together on accelerating the development of new treatment regimens for tuberculosis. Otsuka participates as an industry member.
• AMR Industry AlliancecoreStrategic or Co-development PartnerIndustry alliance contributing to the necessary response by relevant industries to combat antimicrobial resistance. Otsuka is a member contributing to AMR stewardship efforts.
• Industry Declaration on Combating Antimicrobial ResistanceminorStrategic or Co-development PartnerOtsuka is a signatory to the Industry Declaration reiterating commitments to fighting drug resistance through innovative solutions meeting public health needs and improving access to high-quality antibiotics.
• Otsuka Pharmaceutical Co., Ltd.coreStrategic or Co-development PartnerParent company and affiliate. Otsuka Novel Products GmbH is an affiliate of Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Tokyo, Japan. Parent company discovered delamanid compound in Tokushima, Japan.
• Otsuka Pharmaceutical Europe LtdcoreStrategic or Co-development PartnerJoint controllers with Otsuka Pharmaceutical Europe Ltd, Gallions, Wexham Springs, Framewood Road, Wexham, Bucks, SL3 6PJ for processing of medical information data.
• Arvato SEminorOthersThird-party logistics provider handling returns of products. Contact information: [email protected]. Organizes pickup for shipment of returned products.
• World Health Organization (WHO)minorOthersOtsuka references WHO Global Tuberculosis Report 2025 as primary data source for TB statistics. Company's mission aligned with WHO TB elimination goals.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cipla: One of the largest suppliers of anti-tubercular fixed-dose combinations globally, headquartered in India. Directly competes in the TB therapeutics market, especially in high-burden LMICs where Otsuka is seeking to expand access.
• Lupin Pharmaceuticals: Indian multinational with a TB franchise spanning first-line and second-line anti-TB regimens. Operates directly in the same indication and frequently overlaps in tender-driven LMIC supply.
• Macleods Pharmaceuticals: Indian generics manufacturer with a significant anti-tuberculosis portfolio, supplying global TB programmes (including via the Global Fund). A direct competitor in commoditized and MDR-TB formulations.
• Janssen Pharmaceuticals (Johnson & Johnson): Maker of bedaquiline (Sirturo), the most direct therapeutic competitor to Otsuka Novel Products' delamanid in the MDR-TB space. Both companies compete for inclusion in MDR-TB regimens globally and for share of voice with WHO and national TB programmes.

Broad incumbents

• Sanofi: Global pharmaceutical major with a historical TB franchise (including rifapentine) and broader infectious disease portfolio. Competes more broadly than Otsuka Novel Products but overlaps in TB drug development and supply.
• Pfizer Inc. Global pharmaceutical major with infectious disease capabilities and broader respiratory product portfolios (e.g., MDR-pneumonia therapies). Not a focused TB competitor but a credible adjacent incumbent in global infectious disease therapeutics.
• Bayer AG: Large German pharmaceutical company co-headquartered in the same country (Leverkusen) as Otsuka Novel Products' Munich office. A broader pharma incumbent with infectious disease assets and a much larger portfolio.
• Otsuka Pharmaceutical Co., Ltd. Parent company and affiliate based in Tokyo. Operates a far broader pharmaceutical portfolio across psychiatry, nephrology, and other therapeutic areas; serves as the global pharmaceutical parent that discovered delamanid at the Tokushima facility.

Emerging players

• Tb Alliance (Global Alliance for TB Drug Development): Product development partnership that advances new TB regimens (e.g., pretomanid-containing regimens). Both an active partner (via UNITE4TB / PAN-TB) and a competitor shaping the standard-of-care landscape in which Deltyba competes.

Others

• Evotec SE: Contract research organization participating in PAN-TB and adjacent TB drug discovery consortia. An ecosystem player enabling TB R&D rather than a direct commercial competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/otsuka-novel-products-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Novel Products